A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET.

Trial Profile

A Five-Tier, Phase 2 Open-Label Study of IMC-A12 Administered as a Single Agent Every 2 Weeks in Patients With Previously- Treated, Advanced or Metastatic Soft Tissue and Ewing's Sarcoma/PNET.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2014

At a glance

  • Drugs Cixutumumab (Primary)
  • Indications Ewing's sarcoma; Leiomyosarcoma; Neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma
  • Focus Therapeutic Use
  • Sponsors ImClone Systems
  • Most Recent Events

    • 08 May 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
    • 08 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Mar 2012 This trial has been recruiting in Belgium, Germany, Netherlands and France and completed in Spain as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top